- Report
- February 2026
- 250 Pages
Global
From €4088EUR$4,490USD£3,522GBP
- Report
- June 2026
- 190 Pages
Global
From €3228EUR$3,545USD£2,781GBP
€3587EUR$3,939USD£3,090GBP
- Report
- December 2025
- 200 Pages
Global
From €2723EUR$2,990USD£2,346GBP
- Report
- February 2026
- 250 Pages
Global
From €4088EUR$4,490USD£3,522GBP
- Report
- June 2026
- 485 Pages
Global
From €5327EUR$5,850USD£4,589GBP
- Report
- June 2026
- 483 Pages
Global
From €5327EUR$5,850USD£4,589GBP
- Report
- June 2026
- 377 Pages
Global
From €5327EUR$5,850USD£4,589GBP
- Report
- January 2026
- 186 Pages
Global
From €4098EUR$4,500USD£3,530GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2540EUR$2,789USD£2,188GBP
- Report
- November 2025
- 196 Pages
Global
From €4507EUR$4,950USD£3,883GBP
- Report
- June 2025
- 200 Pages
United States
From €2267EUR$2,490USD£1,953GBP
- Report
- August 2022
- 115 Pages
Global
From €4098EUR$4,500USD£3,530GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2276EUR$2,500USD£1,961GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1138EUR$1,250USD£981GBP
- Report
- August 2024
- 233 Pages
Global
From €7239EUR$7,950USD£6,237GBP
- Report
- January 2024
- 395 Pages
Global
From €6829EUR$7,500USD£5,884GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2540EUR$2,789USD£2,188GBP
- Report
- May 2024
- 132 Pages
Global
From €3641EUR$3,999USD£3,137GBP
- Report
- May 2024
- 138 Pages
Global
From €3641EUR$3,999USD£3,137GBP
- Report
- May 2024
- 128 Pages
Global
From €3641EUR$3,999USD£3,137GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more